A 46-residue synthetic peptide engineered as a D-retro-inverso analog of the FOXO4 protein interaction domain. This review covers the published preclinical literature on cellular senescence research, the structural distinction of D-amino-acid peptides versus standard L-amino-acid peptides, and the regulatory status of the compound as of 2026.
THE ORIGIN FRAGMENT: Senescent cells are damaged cells that refuse to undergo apoptosis (programmed cell death), instead secreting toxic inflammatory signals that age surrounding tissue. In 2017, researchers at Erasmus University Medical Center engineered a 46-residue peptide to hunt these specific cells. By utilizing D-amino acids in a reversed sequence—a masterclass structural design called D-retro-inverso (DRI)—they created a compound that is virtually immune to enzymatic degradation in vivo.
PRECLINICAL RESEARCH VECTORS & MECHANISMS FOXO4-DRI is currently at the absolute bleeding edge of senolytic and longevity research. The full dossier covers:
p53 Interaction Disruption: How the peptide competitively binds to p53, severing its bond with FOXO4 and forcing the senescent cell into apoptosis.
Selective Clearance: Cellular assays demonstrating the targeted destruction of senescent cells without harming viable, healthy tissue.
Stereochemical Analysis: The complex RP-HPLC and mass spectrometry protocols required to verify a 46-residue D-retro-inverso synthesis.
PROCUREMENT & COMPLIANCE PROTOCOL Strictly synthesized and supplied for in vitro research, analytical characterization, and laboratory mass spectrometry. Not for human use.
[ Request Full 40-Page Dossier ↗ ] | [ Procure for Research ↗ ]
